A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors.

Trial Profile

A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Seribantumab (Primary) ; Cabazitaxel; Carboplatin; Gemcitabine; Pemetrexed
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Nov 2013 Planned End Date changed from 1 Feb 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 05 Jun 2013 Results in 43 patients presented at the 2013 American Society of Clinical Oncology Annual Meeting, according to Merrimack Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top